Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > REGULATORY
REGULATORY
- MHLW Approves 45 New Compounds in 2012: Mr Akagawa of PFSB
March 6, 2013
- MHLW Aims to Submit Bill to Amend PAL During Current Diet Session: PFSB Director-General Jun Ebata
March 6, 2013
- PAFSC Second Committee to Discuss Pfizer’s Xeljanz and Bayer’s Stivarga on March 13
March 5, 2013
- PAFSC First Committee on New Drugs to Discuss Approval of New Parkinson’s Disease Agent and DPP-4 Inhibitor Onglyza
March 5, 2013
- Health and Education Ministries along with Drug Makers to Start Intractable Disease Research using iPS Cells
March 5, 2013
- Lawmakers Organizing Non-Partisan Group to Break Deadlock on Establishment of 3rd-Party Drug Administration Watchdog Organization
March 5, 2013
- Generic Share by Volume Rose to 28.7% in September 2012, MHLW Reports
March 4, 2013
- Tokyo District Court Dismisses Takeda’s Actos Litigation Against 10 Companies; No Appeal Planned
March 4, 2013
- Japan’s Average Drug Price is 1.44 Times Higher than Europe: MHLW Tally
March 1, 2013
- MHLW’s Health and Medical Strategy HQ Aims to Draft a Final Plan by May
February 28, 2013
- Pharmacies’ Generic Drug Dispensing Rate Rises to 29.4%: Survey Reported to CSIMC
February 28, 2013
- 5 Years Too Long to Achieve Reference Generic Share Target of 60%: Bill Payer Reps at CSIMC Subcommittee
February 28, 2013
- Shuji Shirakawa of Kenporen Says Long-Listed Product Price Cuts Irrelevant to New Drug Development Premium
February 28, 2013
- Participation in TPP Talks “Will Not Damage” Japan’s Universal Health Insurance System: Health Minister Tamura
February 27, 2013
- PAFSC’s 2nd Committee Recommends Approval for CMIC’s Acute Porphyria Treatment
February 27, 2013
- JMACCT Revamps Database of Clinical Trial Institutions; Details Now Available Online
February 27, 2013
- MHLW Launches HQ to Promote Health and Medical Strategy
February 27, 2013
- Doctors' Average Monthly Wage Reaches 789,300 Yen in 2012, MHLW Survey Shows
February 25, 2013
- Govt Launches New Office of Health and Medical Strategy
February 25, 2013
- Ruling Parties’ Commission on Reduced Consumption Tax Rate System to Issue Interim Report This Summer
February 22, 2013
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…